Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Placebo-controlled, Double-blinded, Randomized Clinical Trial of Anti-TNF Chimeric Monoclonal Antibody (cA2) in Korean Patients With Active Rheumatoid Arthritis Despite Methotrexate Treatment (Open-label Extension Part)
Brief Summary: This trial is extension part of the P04280 (placebo-controlled, double-blind, randomized study of chronic treatment with infliximab in approximately 140 patients, NCT00202852). This study will be conducted at 6 study centers in South Korea. After completion of the last follow-up visit at Week 30 and code break in main double-blind trial, subjects randomized to the placebo group and those who were treated with an infliximab-containing regimen who maintained clinical response at the time of study completion will be provided with open-label infliximab for treatment of their conditions and additional safety data will be collected.


Options:
A: Arm Label: Sequence 1; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Sequence 2; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Sequence 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: CP-690,550 | Arm Label: Sequence 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: CP-690,550 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Sequence 1 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Sequence 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Sequence 3 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Sequence 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Sequence 4 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Sequence 4
B: Arm Label: Abatacept + Methotrexate; Type: EXPERIMENTAL; Interventions: Drug: Abatacept, Drug: Methotrexate | Arm Label: Placebo + Methotrexate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate, Drug: Placebo | Arm Label: Abatacept + Methotrexate Open Label; Type: EXPERIMENTAL; Interventions: Drug: Abatacept, Drug: Methotrexate | Intervention Type: DRUG; Name: Abatacept; Assigned to Arm(s): Abatacept + Methotrexate, Abatacept + Methotrexate Open Label | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Abatacept + Methotrexate, Abatacept + Methotrexate Open Label, Placebo + Methotrexate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + Methotrexate
C: Arm Label: 5 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: 15 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: 30 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 5 mg BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 15 mg BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 30 mg BID | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Open Label Infliximab + Methotrexate; Type: EXPERIMENTAL; Interventions: Biological: Infliximab + methotrexate (MTX) | Intervention Type: BIOLOGICAL; Name: Infliximab + methotrexate (MTX); Assigned to Arm(s): Open Label Infliximab + Methotrexate

Answer: D